TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1936480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 21 mg of glibenclamide and 1.5 g of metformin
Study: 30455233
Drug: Mefloquine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (two 15-mg/kg doses at least 1 month apart)
Study: 27225013
Drug: Micronised progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised progesterone (Utrogestan(®), Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Study: 27225013
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal capsules administered twice daily from soon after a positive urinary pregnancy test until 12 completed weeks of gestation.
Study: 20237041
Drug: Bowel preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel preparation (n = 26)
Study: 20237041
Drug: Native group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native group (no bowel preparation) (n = 39)
Study: 16252380
Drug: Fluoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine alone (control group, n=51)
Study: 14741060
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d donepezil
Study: 7872324
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium dialysate (2.00 mEq/L; LCa)
Study: 7872324
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium dialysate (3.5 mEq/L; SCa)
Study: 24498872
Drug: Treatment choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment choice of supportive care or cytarabine
Study: 19694743
Drug: Gefitinib after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib after 5 days treatment with phenytoin (5 mg kg(‐1) daily)
Study: 17375635
Drug: Topical pharyngeal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pharyngeal anesthesia alone
Study: 9785068
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (40 mg)
Study: 12806612
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac (100 mg)
Study: 17171950
Drug: Beta-blockers (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (in groups B-P and B-V)
Study: 29889693
Drug: Quadrivalent human
Normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human papillomavirus vaccine
Study: 15990257
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/daily)
Study: 15990257
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA (0.625 mg/daily + 2.5 mg/daily)
Study: 15990257
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + NA (0.625 mg/daily + 5 mg/daily)
Study: 15990257
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg once daily)
Study: 23959544
Drug: Control (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (N w‐nitro‐L‐arginine, Ro 31‐8220)
Study: 15013654
Drug: Biofeedback-assisted behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-assisted behavioral therapy
Study: 15013654
Drug: Oxybutynin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin therapy
Study: 11396779
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg selenium as L-selenomethionine during pregnancy and 12 months postpartum
Study: 25606338
Drug: Bioptron light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioptron light therapy (8 sessions, 3 times a week)
Study: 20650377
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 0.5 mg neostigmine
Study: 1998761
Drug: Perindopril 2‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2‐8 mg daily
Study: 1998761
Drug: Nifedipine 20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20‐80 mg daily
Study: 1998761
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Perindopril and Nifedipine)
Study: 6689152
Drug: Standard Pro‐Banthine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Pro‐Banthine 15 mg tablets
Study: 30841858
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily for six weeks
Study: 29559724
Drug: Individualised dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualised dietary advice supplemented with 30 g walnuts/day (IW)
Study: 10210048
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous technique (T group, n = 15) consisting of midazolam for induction and propofol for maintenance.
Study: 22373031
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zonal refractive and diffractive aspheric MIOLs
Study: 11315837
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg daily orally)
Study: 11315837
Drug: GLP-1 (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 (continuous subcutaneous infusion of 2.4 pmol x kg(‐1) x min(‐1))
Study: 9006356
Drug: Carbogen inhalation
Normalized name: carbogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbogen inhalation therapy
Study: 25275613
Drug: First analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: First analgesic treatment with positive or negative experiences (details on dosage and duration not provided)
Study: 25275613
Drug: Second different
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second different analgesic treatment (details on dosage and duration not provided)
Study: 21877951
Drug: 6,000 mg
Normalized name: cranberry conc/ascorbic acid 6,000 mg-100 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6,000 mg of dried rosemary leaf powder
Study: 12466015
Drug: Low Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Sodium Treatment (LS: 143 10 mM)
Study: 12466015
Drug: High Sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Sodium Treatment (HS: 434+/‐17 mM Na+/d excreted)
Study: 2644051
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg.kg‐1 administered as a single bolus
Study: 22354739
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg
Study: 18165571
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and remifentanil target-controlled infusion with randomized remifentanil targets ranging from 2 to 8 ng/mL, with half receiving neuromuscular blockade.
Study: 8709688
Drug: Single 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 g oral dose of ciprofloxacin
Study: 8709688
Drug: Single 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300 mg oral dose of doxycycline
Study: 8709688
Drug: Single 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300 mg oral dose of doxycycline (tetracycline-resistant strain)
Study: 8709688
Drug: Single 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300 mg oral dose of doxycycline (tetracycline-susceptible strain)
Study: 2018224
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of midazolam
Study: 4088460
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg)
Study: 6750325
Drug: graded sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: graded sequential mestranol and norethisterone
Study: 31775152
Drug: 0 ppm
Normalized name: Sodium Fluoride 5000 PPM
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0 ppm F dentifrice/gel (H0/L0)
Study: 31775152
Drug: 1,450 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,450 ppm F dentifrice/gel (H1,450/L1,450)
Study: 31775152
Drug: 5,000 ppm
Normalized name: Oxygen 995,000 ppm gas for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 ppm F dentifrice/gel (H5,000/L5,000)
Study: 31775152
Drug: 12,500 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12,500 ppm F dentifrice/gel (H12,500/L12,500)
Study: 31775152
Drug: 5,000 ppm
Normalized name: Oxygen 995,000 ppm gas for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 ppm F plus TCP dentifrice/gel (H5,000+TCP/L5,000+TCP)
Study: 27566056
Drug: Submucosal injection
Normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submucosal injection papillectomy (SIP)
Study: 19056607
Drug: Threonine intake
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Threonine intake ranging from 10 to 100 mg . kg(‐1) . d(‐1)
Study: 19366842
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human luteinizing hormone (rhLH)
Study: 26749760
Drug: No dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dressing spray applied (control group)
Study: 23957658
Drug: Generx (Ad5FGF4)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generx (Ad5FGF4) administered via intracoronary route
Study: 11164665
Drug: Oxandrolone (anabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (anabolic steroid)
Study: 9333788
Drug: Theophylline chewable
Normalized name: theophylline Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline chewable tablet (100 mg)
Study: 9333788
Drug: Theophylline solution
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline solution (reference)
Study: 8492277
Drug: Vermifuge treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vermifuge treatment
Study: 2686393
Drug: Doxorubicin (D)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (D) alone (60 mg/m2, observation after 500 mg/m2)
Study: 2686393
Drug: Doxorubicin (D)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (D) combined with Vincristine (V) and Mitomycin C (M) (D: 50 mg/m2, V: 1 mg/m2, M: 10 mg/m2, given every other cycle)
Study: 28623892
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SWSCM program plus access to an online information and support resource (MISTT website)
Study: 23228436
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy/Cognitive Behavior Therapy (MET/CBT)+Parent Management Training+Contingency Management (CM)
Study: 19727022
Drug: Protease supplementation
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease supplementation (5.83 g daily)
Study: 9203116
Drug: Form 90
Normalized name: oxygen 90 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form 90 (structured interview for assessing alcohol treatment outcomes)
Study: 29888715
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy group
Study: 22843306
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: Anesthesia induced as in group I; maintained with isoflurane inhalation combined with propofol-remifentanil infusion.
Study: 10418709
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo prompt gamma neutron activation analysis using a 252Cf neutron source, 40 min duration, mean whole-body equivalent dose of 0.25 mSv
Study: 6791201
Drug: Amitriptyline (AT)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AT) 100 mg
Study: 30679095
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin glargine (IGlar)
Study: 15064016
Drug: Misonidazole (MISO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (MISO), n = 39, given orally at a dose of 0.45 g/m(2) 4 hours prior to radiation treatment and during brachytherapy (40Gy)
Study: 7648803
Drug: Dexfenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (30 mg d‐1 for initial 3 months)
Study: 2501593
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy without DFMO
Study: 20085679
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 400 mg three times daily from 36 weeks' gestation
Study: 11350782
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion to achieve moderate (approximately 75 pmol/l) and high (approximately 150 pmol/l) physiological insulin levels during hyperinsulinemic‐hyperglycemic clamps.
Study: 2352468
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of fentanyl 0.0005%
Study: 23334675
Drug: Desvenlafaxine 25
Normalized name: DESVENLAFAXINE 25 mg ORAL TABLET, EXTENDED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 25 mg/day
Study: 21834921
Drug: Omega-3 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 and omega-6 fatty acids supplementation (3 capsules daily)
Study: 19567409
Drug: Piboserod 80
Normalized name: Piboserod
DrugBank: Piboserod (DB04873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piboserod 80 mg for 24 weeks
Study: 17352805
Drug: Early surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surgical treatment (within one week)
Study: 8790024
Drug: Xemilofiban (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xemilofiban (5, 10, 15, or 20 mg) administered 8 to 18 hours after abciximab termination
Study: 8790024
Drug: Placebo (ticlopidine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ticlopidine) administered 8 to 18 hours after abciximab termination
Study: 1734217
Drug: Daunorubicin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (30 mg/m2) in combination with vincristine, prednisone, and L-asparaginase (VPLD)
Study: 6380903
Drug: Schering gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schering gentamicin 1 mg/kg
Study: 6380903
Drug: Invenex gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invenex gentamicin 1 mg/kg
Study: 30171400
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (control, C)
Study: 22381603
Drug: 17P treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17P treatment and Control group.
Study: 7021410
Drug: Domiciliary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary treatment with isoniazid and PAS for one year in 3 treatment towns
Study: 7021410
Drug: Domiciliary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary treatment with isoniazid alone for one year in 3 treatment towns
Study: 7021410
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no special facilities for diagnosis or treatment
Study: 30273086
Drug: Mind-body intervention
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body intervention as an adjunct to SUD treatment
Study: 11481349
Drug: gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1,000 mg/m2
Study: 9669426
Drug: Allopurinol (a
Normalized name: allopurinol (as allopurinol sodium) 500 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (a xanthine oxidase inhibitor)
Study: 3074621
Drug: Smaller doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller doses of medications
Study: 3074621
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or other medication
Study: 25475110
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alternate-day aspirin
Study: 17964789
Drug: Albendazole plus
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole plus antiepileptic drugs (group A)
Study: 17964789
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs alone (group B)
Study: 12036523
Drug: Oral dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dipyridamole (75 mg twice a day for 5 days)
Study: 7609566
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and protamine dosing according to in vitro predictive tests integrating drugs, tests, and patient response
Study: 7609566
Drug: Conventional methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methods of heparin and protamine dosing
Study: 29882510
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (TMPP tablet, 200 mg)
Study: 16126045
Drug: Fluconazole prophylaxis
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole prophylaxis (twice weekly for up to 6 weeks)
Study: 12823779
Drug: BL22, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL22, a fusion of an anti‐CD22 antibody linked to a portion of the Pseudomonas exotoxin A
Study: 19233341
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg every other day)
Study: 10193737
Drug: High fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fibrinogen levels (>=343 mg/dl)
Study: 2114029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Rifampicin, Isoniazid, and Pyrazinamide (administered separately or in combined preparations)
Study: 22374408
Drug: Glimepiride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (4 mg)
Study: 21430255
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g butter (rich in SFA)
Study: 11934542
Drug: Very low-energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low-energy diet therapy for 4 weeks
Study: 31210019
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg subconjunctival injection of triamcinolone acetonide (TA)
Study: 31210019
Drug: 1 mg/ml
Normalized name: urea 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/ml dexamethasone eye drops (DEX)
Study: 25580605
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (SXB) 3 g, 6 g, and 9 g nightly
Study: 23900468
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g corn oil daily)
Study: 19831166
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application using fingertip
Study: 19831166
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application using fingertip followed by seven days of brushing
Study: 19831166
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application using cotton swab followed by seven days of brushing
Study: 11701449
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) with ibuprofen
Study: 11701449
Drug: Control (ibuprofen)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (ibuprofen)
Study: 3297890
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 34 +/‐ 4 microU/ml
Study: 31833053
Drug: Tailored therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored therapies and disease monitoring
Study: 29273021
Drug: Standard community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard community mental health team care (treatment as usual)
Study: 31267684
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg every other day
Study: 31267684
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg every other day + l-arginine 3 g/day orally
Study: 10783343
Drug: decapeptyl-GnRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: decapeptyl-GnRH (100 microgram) daily injected from day 1 to triggering of ovulation
Study: 10783343
Drug: decapeptyl-GnRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: decapeptyl-GnRH (100 microgram) daily injected for the first 7 days
Study: 24016560
Drug: Different treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatment options for flat type of sudden hearing loss
Study: 8922792
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg daily
Study: 1633070
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg daily
Study: 7742428
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg to 400 mg daily)
Study: 2167795
Drug: Dye dilution
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dye dilution method (Indocyanine Green dye infusion into the femoral artery)
Study: 19901104
Drug: RT followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT followed by adjuvant PCV chemotherapy